<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307800</url>
  </required_header>
  <id_info>
    <org_study_id>12430</org_study_id>
    <secondary_id>H8Y-MC-HBBN</secondary_id>
    <nct_id>NCT01307800</nct_id>
  </id_info>
  <brief_title>A Study of LY2140023 in Patients With Schizophrenia</brief_title>
  <official_title>A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to
      acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as
      compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The decision to stop the trial was based on efficacy results in the overall schizophrenia
    participant population.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the PANSS total score in a predefined genetic subpopulation of schizophrenia patients</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Personal and Social Performance (PSP) score in a predefined subpopulation</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the PSP score</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who are responders</measure>
    <time_frame>Baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 16-item Negative Symptoms Assessment (NSA-16)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on EuroQOL - 5 dimension (EQ-5D) Questionnaire</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Schizophrenia Resource Utilization Model (S-RUM)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on Subjective Well-Being Under Neuroleptic Treatment Scale - Short Form (SWN-S)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Barnes Akathisia Scale (BAS)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simpson-Angus Scale (SAS)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Abnormal Involuntary Movement Scales (AIMS)</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with suicidal behaviors and ideations measured by the Columbia-Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>Baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of discontinuation</measure>
    <time_frame>Baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation</measure>
    <time_frame>Baseline up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the PANSS subscores</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Prolactin</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the PANSS total score in females</measure>
    <time_frame>Baseline, Up to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>80 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg LY2140023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered orally, BID for up to 7 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>80 mg LY2140023</arm_group_label>
    <arm_group_label>40 mg LY2140023</arm_group_label>
    <arm_group_label>10 mg LY2140023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia as defined in the Diagnostic and Statistical Manual of
             Mental Disorders, Fourth Edition, Text Revision DSM-IV-TR; and confirmed by the
             Structured Clinical Interview for DSM-IV-TR (SCID)

          -  Non pregnant female patients who agree to use acceptable birth control

          -  Participants must be considered moderately ill in the opinion of the investigator

          -  Patients in whom a modification of antipsychotic medication or initiation of
             antipsychotic medication is acutely indicated in the opinion of the investigator

          -  Willing to participate in a minimum of 2 weeks of inpatient hospitalization.

          -  One year history of Schizophrenia prior to entering the study

          -  At study entry patients with a history of antipsychotic treatment must have a lifetime
             history of at least one hospitalization for the treatment of schizophrenia, not
             including the hospitalization required for study. Patients who have never taken
             antipsychotic treatment may enter the study even without a history of hospitalization

          -  At study entry patients with a history of antipsychotic treatment must have a history
             of at least one episode of illness exacerbation requiring an intensification of
             treatment intervention or care in the last 2 years, not including the present episode
             of illness. Patients who have never taken antipsychotic treatment may enter the study
             without a past history of illness exacerbation and intensification of treatment in the
             last 2 years

          -  At study entry patients must have experienced an exacerbation of illness within the 2
             weeks prior to entering the study, leading to an intensification of psychiatric care
             in the opinion of the investigator. If exacerbation occurs in patients who are
             presently hospitalized, the patient must not have been hospitalized longer than 60
             days at entry of the study

          -  Patients must be considered reliable and have a level of understanding sufficient to
             perform all tests and examinations required by the protocol, and be willing to perform
             all study procedures

        Exclusion Criteria:

          -  Patients who have a history of inadequate clinical response to antipsychotic treatment
             for schizophrenia

          -  Diagnosis of substance dependence or substance abuse within 6 month of study entry

          -  Diagnosis of substance-induced psychosis within 7 days of study entry

          -  Currently enrolled in, or discontinued within 6 months from a clinical trial involving
             an investigational product or unapproved use of a drug or device

          -  Participated in any clinical trial with any pharmacological treatment intervention for
             which they received a study-related medication in the 6 months prior to study entry

          -  Previously completed or withdrawn from this study, or any other study investigating
             LY2140023 or any predecessor molecules with glutamatergic activity

          -  Treatment with clozapine at doses greater than 200 mg daily within 12 months prior to
             entering the study, or who have received any clozapine at all during the month before
             study entry

          -  Patients currently receiving treatment (within 1 dosing interval, minimum of 4 weeks,
             prior entering the study) with a depot formulation of an antipsychotic medication

          -  Patients who are currently suicidal

          -  Females who are pregnant, nursing, or who intend to become pregnant within 30 days of
             completing the study

          -  Patients with uncorrected narrow-angle glaucoma, uncontrolled diabetes, certain
             diseases of the liver, renal insufficiency, uncontrolled thyroid condition or other
             serious or unstable illnesses

          -  Have a history of one or more seizures

          -  Electroconvulsive therapy (ECT) within 3 months of entering the study or who will have
             ECT at any time during the study

          -  History of low white blood cell count

          -  Medical history of Human Immunodeficiency Virus positive (HIV+) status.

          -  Higher than normal blood prolactin levels

          -  Abnormal electrocardiogram results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lipetsk</city>
        <zip>399007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>109559</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Voronezh</city>
        <zip>394071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Donetsk</city>
        <zip>83037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kiev</city>
        <zip>2660</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <disposition_first_submitted>January 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 11, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 21, 2013</disposition_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

